Financing

Business financing
#Artificial intelligence (AI) #Drug development #Drug discovery #Financing

Tres Alchemix closes $4.4 million financing round

AI-driven biotechnology company Tres Alchemix has closed its $4.4 million Series A financing round, the company has announced.  New funding will be used to accelerate the development of Tres Alchemix’s predictive AI platform and support the opening of a new laboratory at The Oxford Science Park, a hub of world-leading… Read More

#Business & Investment #News #Start-up Zone

Haematology
#Biotech #Financing #Haematology #Immunology

Star Therapeutics announces $125 million financing for VWD therapy

Biotechnology company Star Therapeutics has announced its $125 million Series D financing round was oversubscribed and will now initiate a clinical trial of its von Willebrand disease (VWD) therapy.  The financing round was co-led by Sanofi Ventures and Viking Global Investors, with participation from both… Read More

#News

#AI #Drug discovery #Financing

DaltonTx set to build AI-enabled drug discovery platforms

UK-based technology company DaltonTx has announced the completion of a £4 million ($5.4 million) financing round to build adaptive AI-enabled drug discovery platforms.  The company, which exited from stealth, is planning on building platforms giving research teams instant access to AI-enabled drug discovery, bypassing their need for… Read More

#News

Antibodies
#Bispecific Antibodies #Financing

Dualitas Therapeutics to develop next-gen specific antibodies

Biotechnology company Dualitas Therapeutics has launched from stealth with a $65 million (£48 million) Series A financing round to develop next-generation bispecific antibodies (BsAbs).  The company’s financing is co-led by Versant Ventures and Qiming Venture Partners USA, with participation from founding investor SV Health Investors and new… Read More

#News

UK
#Financing #Investment #Life sciences #Start-ups #UK

Growing investor interest in later-stage UK life science companies

New research into the UK life sciences landscape has revealed a growing trend of investment into more mature companies.   Pioneer Group’s ‘Life Science Start Up Report’ also highlights a persistent regional imbalance, with ‘Golden Triangle’ university spinouts attracting significantly more funding than those elsewhere.  Whilst the number of deals in… Read More

#Business & Investment #News #Start-up Zone

Business financing
#Financing #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics raises $153 million for mRNA therapies

Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.  The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumour microenvironment.   The company recently… Read More

#Business & Investment #News

#Financing #Funding #MapLight Therapeutics #Neuroscience

MapLight Therapeutics makes $372.5m in series D financing

MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing.   The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T Rowe Price Investment Management, Inc. and Avego BioScience Capital.   The financing also included strong… Read More

#Business & Investment #News

#Cancer research #Cell profiling #Drug development #Financing #Next generation sequencing #One Biosciences

€15 million to advance clinical single cell profiling

One Biosciences has raised €15 million in Series A financing to advance its clinical grade single-cell tumour transcriptomic profiling capabilities. The financing was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures. This round brings One Biosciences' total funding… Read More

#Business & Investment #News

#Actithera #Financing #Radioligand Therapies (RLTs) #Radiopharmaceuticals

Actithera raises $75.5m to support its precision radioligand therapies

Radiopharmaceutical biotech company Actithera has closed an oversubscribed $75.5 million Series A financing round.   The financing will support the advancement of Actithera’s lead fibroblast activation protein (FAP)-targeting asset into clinical development in multiple indications, while also enabling the continued development of its radioligand therapies (RLT) discovery platform and preclinical pipeline. … Read More

#Business & Investment #News

#Drug discovery #Financing #Non-animal model (NAM) #Organoids #Parallel Bio

Parallel Bio secures $21m to advance human-first drug discovery

Biotech company Parallel Bio has raised $21 million in a Series A funding led by AIX Ventures.   The round attracted new investors Amplo and Marc Benioff, founder and CEO of Salesforce, and existing investors Metaplanet, Humba Ventures, Atypical Ventures, Undeterred Capital, and Jeff Dean.   Robert DiFazio, CEO and Co-Founder at… Read More

#Business & Investment #News

Cell and gene therapy
#AAV #Financing #Gene therapy #Genetic diseases #Ophthalmology #SpliceBio

SpliceBio secures $135m to advance gene therapy candidates

SpliceBio has closed a $135 million Series B financing co-led by new investors EQT Life Sciences and Sanofi Ventures.  There was also participation from Roche Venture Fund, as well as all existing investors: New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.  The funding… Read More

#Business & Investment #News

#Financing #Immunotherapy #Oncology #Ovarian cancer #Scandinavia

TILT Biotherapeutics closes $25 million Series B financing

Finnish biotechnology company TILT Biotherapeutics (Tiltbio) has raised $25.6 million (€22.6 million) in a Series B financing.  The financing will support a Phase II clinical trial of Tiltbio’s lead product, TILT-123, in patients with platinum-resistant epithelial ovarian cancer, a Phase Ib trial in melanoma in combination with TILs and other… Read More

#Business & Investment #News

#Augustine Therapeutics #Financing #Neuropathy #Spinout

Biotech raises €78 million to advance HDAC6 inhibition therapies

Augustine Therapeutics has raised €78 million to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases. The proceeds from the financing will advance Augustine’s lead candidate, AGT-100216, through a Phase II proof-of-concept clinical trial in Charcot-Marie-Tooth and support significant pipeline expansion.  Jeito Capital, a global independent Private Equity fund, and… Read More

#Business & Investment #News

#ALS #Arbor Biotechnologies #CNS #Financing #Gene therapy

Gene editing company announces $73.9m Series C financing

Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).   The proceeds will support clinical development of the company’s lead therapeutic candidate, ABO-101, in primary… Read More

#Business & Investment #News

#Acute inflammatory conditions #Financing #GPCRs #Maxion Therapeutics #Therapeutic Antibodies

Maxion Therapeutics raises $72m to advance KnotBody pipeline

Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases.  The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and… Read More

#Business & Investment #News

#Cancer research #Cancer therapeutics #Financing #Small molecules #Vivace Therapeutics

Financing secured for cancer drug targeting the Hippo pathway

Vivace Therapeutics has announced the closing of $35 million Series D financing to support the company’s small molecule cancer therapeutics targeting the Hippo pathway. The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. Proceeds will support… Read More

#Cancer Research #News